Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

  Measured over: Up to ~21 days

• Part 1: Number of Participants With Adverse Events (AEs)

  Measured over: Up to ~44 months

• Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE

  Measured over: Up to ~29 months

• Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

  Measured over: Up to ~41 months

• Part 2: OS in All Participants

  Measured over: Up to ~41 months

• Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1

  Measured over: Up to ~29 months

• Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants

  Measured over: Up to ~29 months

Changes Tremor has spotted